ZBH — Zimmer Biomet Holdings, Inc.

Is ZBH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of October 3, 2026

Zimmer Biomet Holdings, Inc. (ZBH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $88.29. The rating moved from Strong Oversold to Oversold on September 29, 2026.

See all oversold Healthcare stocks →

AI analysis

Zimmer Biomet is a well‑positioned orthopedic/device leader with diversified franchises and steady cash generation, supported by secular demand for joint replacement and musculoskeletal care. Near-term market conditions are cautious: elective-procedure sensitivity, macro risk-off flows, and supply‑chain/geopolitical noise limit conviction for a strong directional move without a company-specific catalyst. The company’s financial flexibility and R&D/inorganic capability underpin medium-term growth potential, but competition, reimbursement pressure, regulatory/recall risk and sensitivity to procedure volumes are meaningful headwinds. Social sentiment from recent filings is mildly positive but low impact. Scenario outcomes hinge on procedure volume normalization, successful cost/supply execution, and any material product or commercial wins; conversely, macro weakness or regulatory setbacks could depress volumes and margins.

Key factors

  • Leading market position in musculoskeletal and orthopedic devices with a diversified product portfolio and large installed base
  • Stable historical free-cash-flow and margin profile that supports R&D, targeted M&A and capital returns
  • Long-term secular demand drivers from aging populations and growth in joint replacement volumes globally
  • Near-term sensitivity to elective-procedure volumes and macro-driven risk-off sentiment which has constrained device IPOs and capital flows
  • Limited fresh catalysts evident in the immediate horizon; small positive signals from recent SEC filings but no material corporate news disclosed
  • Exposure to supply-chain volatility and geopolitical risk that has recently driven rotations into defensive assets

Risks

  • Cyclical exposure to elective surgeries — demand can fall materially in risk‑off or recessionary periods
  • Intense competition from large orthopedics peers (e.g., Stryker, DePuy/J&J, Smith+Nephew) leading to pricing pressure and share battles
  • Reimbursement and payer pressure, including downstream effects from broader policy actions on healthcare budgets
  • Regulatory and product recall risk for implants and surgical devices that could impact sales and margins
  • Supply‑chain disruptions, input inflation or FX volatility that could compress near-term profitability
  • M&A and integration execution risk if management pursues larger acquisitions to sustain growth

See today's live rating, score and targets

Members see the live hourly rating for ZBH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.